Loading clinical trials...

A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD | Clinical Trials | Clareo Health

COMPLETEDPHASE3

A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD

A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, FLUOXETINE-REFERENCED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF DESVENLAFAXINE SUCCINATE SUSTAINED RELEASE (DVS SR) IN THE TREATMENT OF CHILDREN AND ADOLESCENT OUTPATIENTS WITH MAJOR DEPRESSIVE DISORDER

NCT01372150•Pfizer

View on ClinicalTrials.gov

Summary

This is a Double-blind Study Evaluating Desvenlafaxine Succinate (DVS SR) Sustained Release vs Placebo in the Treatment of Children and Adolescent Outpatients with Major Depressive Disorder (MDD).

Eligibility

Age

7 - 17 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Age \>=7 and \<18 years of age
•Primary diagnosis of major depressive disorder (MDD)
•CDRS-R score \>40

Exclusion Criteria

•History of suicidal behaviour, or requires precaution against suicide
•Not in generally healthy medical condition
•History of psychosis or bipolar disorder
•Seizure disorder

Locations (43)

Harmonex Neuroscience Research, Inc.

Dothan, Alabama, United States

Dedicated Clinical Research

Goodyear, Arizona, United States

University of Arizona Clinical and Translational Science Center (CATS)

Tucson, Arizona, United States

University of Arizona College of Medicine Dept of Psychiatry

Tucson, Arizona, United States

Arkansas Psychiatric Clinic Clinical Research Trials, P.A.

Little Rock, Arkansas, United States

ATP Clinical Research, Inc. 1

Costa Mesa, California, United States

Behavioral Research Specialists, LLC

Glendale, California, United States

Synergy Clinical Research Center

National City, California, United States

Neuropsychiatric Research Center of Orange County

Orange, California, United States

Pacific Clinical Research Medical Group

Orange, California, United States

Key Dates

Start Date

November 17, 2011

Primary Completion Date

March 20, 2015

Completion Date

March 20, 2015

Last Updated

January 15, 2019

Enrollment

340

ACTUAL participants

Conditions

Major Depressive Disorder

Interventions

desvenlafaxine succinate sustained release

DRUG

fluoxetine

DRUG

placebo

DRUG

A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder

NCT07115329

Major Depressive Disorder

View study

RECRUITINGPHASE3

A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

NCT06793397

Major Depressive Disorder (MDD)Depression in Adults+4 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 15, 2019Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD

Inclusion Criteria

Exclusion Criteria

A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder

A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

Accelerated Intermittent Theta Burst Stimulation for Adolescent and Young Adult Depression With Elevated Suicide Risk

Validating the On-line Creyos Cognitive Assessment Platform in Older Adults With Major Depressive Disorder or Mild Cognitive Impairment

University of Iowa Interventional Psychiatry Service Patient Registry

Optimized Predictive Treatment In Medications for Unipolar Major Depression (OPTIMUM-D)